Guselkumab is a fully human monoclonal antibody that acts as a blocker of IL-23. The ongoing pivotal phase 3 trials VOYAGE 1 and 2 have demonstrated significant efficacy of guselkumab for the treatment of moderate-to-severe plaque psoriasis in comparison with an active comparator and placebo. The current investigation analysed pooled data from VOYAGE 1 and 2 with regard to long-term efficacy in patients with or without psoriatic arthritis (PsA) .
In VOYAGE 1, over 800 patients were treated with either (1) 100 mg guselkumab at week 0, 4, and 12, and then every 8 weeks, (2) placebo at week 0, 4, and 12, followed by guselkumab at week 16 and 20, and every 8 weeks thereafter; or (3) adalimumab until week 47. From week 52 onwards, all patients received 100 mg guselkumab open-label until week 156. The study design for the nearly 1,000 patients in VOYAGE 2 was similar, but the open-label guselkumab phase in weeks 76-156 was preceded by a randomised withdrawal....
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis Next Article
JAK inhibitors: a new therapeutic tool for dermatologists »
Table of Contents: AAD 2019
Atopic Dermatitis: Many New Therapies in the Pipeline
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
What's New and Hot in Acne
Pearls of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.